Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 9, 2014

Primary Completion Date

January 28, 2021

Study Completion Date

August 6, 2028

Conditions
Refractory Hurthle Cell Thyroid Cancer
Interventions
DRUG

sorafenib

Given PO

DRUG

everolimus

Given PO

Trial Locations (21)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Sleepy Hollow, Sleepy Hollow

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

19111

Fox Chase Cancer Center, Philadelphia

27534

Southeastern Medical Oncology Center-Goldsboro, Goldsboro

Wayne Memorial Hospital, Goldsboro

28328

Southeastern Medical Oncology Center-Clinton, Clinton

28546

Southeastern Medical Oncology Center-Jacksonville, Jacksonville

43210

Ohio State University Comprehensive Cancer Center, Columbus

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

51101

Siouxland Regional Cancer Center, Sioux City

53547

Mercy Health System, Janesville

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

68114

Nebraska Methodist Hospital, Omaha

32224-9980

Mayo Clinic in Florida, Jacksonville

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis

INDUSTRY

lead

Alliance for Clinical Trials in Oncology

OTHER